Sugi Predict

Sugi Predict / Compounds / SCHEMBL2435255

SCHEMBL2435255

SCHEMBL2435255

CCOC(=O)CCc1ccc(O)c2ccccc12

nearest known ligand 0.66

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CYP4F2 P78329 3/20 0.63
▸ CYP4A11 Q02928 3/20 0.63
▸ CYP1A2 P05177 1/20 0.56
▸ CYP3A4 P08684 1/20 0.56
▸ CYP2D6 P10635 1/20 0.56
▸ CYP2C9 P11712 1/20 0.56
▸ CYP2C19 P33261 1/20 0.56
▸ SMN1; SMN2 Q16637 1/20 0.56
▸ LMNA P02545 1/20 0.48
▸ CDYL Q9Y232 1/20 0.47
▸ PKM P14618 1/20 0.47
▸ ALDH1A1 P00352 1/20 0.46
▸ GAA P10253 1/20 0.46
▸ KDM4E B2RXH2 1/20 0.44
▸ TOP2A P11388 1/20 0.44
▸ MAPT P10636 1/20 0.44
▸ ALOX5 P09917 1/20 0.43
▸ CDC25B P30305 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12035852 0.82 CYP4F2 (0.60) CYP4F2CYP4A11CYP1A2CYP3A4CYP2D6
SCHEMBL2650308 0.81 CYP4F2 (0.58) CYP4F2CYP4A11CYP1A2CYP3A4CYP2D6
SCHEMBL1246063 0.81 CYP4F2 (0.76) CYP4F2CYP4A11CYP1A2CYP3A4CYP2D6
SCHEMBL69660 0.80 CYP4F2 (0.86) CYP4F2CYP4A11CYP1A2CYP3A4CYP2D6
SCHEMBL2302173 0.80 CYP4F2 (0.69) CYP4F2CYP4A11CYP1A2CYP3A4CYP2D6
SCHEMBL2437480 0.80 CYP4F2 (0.55) CYP4F2CYP4A11CYP1A2CYP3A4CYP2D6
SCHEMBL490361 0.80 CYP4F2 (0.55) CYP4F2CYP4A11CYP1A2CYP3A4CYP2D6
SCHEMBL9614835 0.79 CYP4F2 (0.60) CYP4F2CYP4A11CYP1A2CYP3A4CYP2D6
SCHEMBL22098182 0.78 CYP4F2 (1.00) CYP4F2CYP4A11CYP1A2CYP3A4CYP2D6
SCHEMBL16048513 0.77 CYP4F2 (0.47) CYP4F2CYP4A11CYP1A2CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3409671-B1 ISOTHIAZOLE DERIVATIVES AS GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES JANSSEN PHARMACEUTICA NV (BE) 2021-07-21 — — EP disclosed
US-10618893-B2 GPR120 agonists for the treatment of type II diabetes JANSSEN PHARMACEUTICALS NV (BE) 2020-04-14 — — US disclosed
US-10618893-B2 GPR120 agonists for the treatment of type II diabetes JANSSEN PHARMACEUTICALS NV (BE) 2020-04-14 — — US disclosed
CN-106414434-B Isothiazole derivatives as GPR120 agonists for the treatment of type II diabetes 詹森药业有限公司 2019-12-31 — — CN disclosed
US-20190071435-A1 GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES JANSSEN PHARMACEUTICA NV (BE) 2019-03-07 — — US disclosed
US-20190071435-A1 GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES JANSSEN PHARMACEUTICA NV (BE) 2019-03-07 — — US disclosed
EP-3409671-A1 ISOTHIAZOLE DERIVATIVES AS GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES Janssen Pharmaceutica NV (BE) 2018-12-05 — — EP disclosed
US-10118922-B2 GPR120 agonists for the treatment of type II diabetes JANSSEN PHARMACEUTICA NV (BE) 2018-11-06 — — US disclosed
EP-3114123-B1 ISOTHIAZOLE DERIVATIVES AS GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES JANSSEN PHARMACEUTICA NV (BE) 2018-04-25 — — EP disclosed
EP-3114123-B1 ISOTHIAZOLE DERIVATIVES AS GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES JANSSEN PHARMACEUTICA NV (BE) 2018-04-25 — — EP disclosed
US-20100190831-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. 2010-07-29 — — US disclosed
US-20100190831-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. 2010-07-29 — — US disclosed
US-20100190831-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. 2010-07-29 — — US disclosed
WO-2010080537-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. (US) 2010-07-15 — — WO disclosed
WO-2010080537-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. (US) 2010-07-15 — — WO disclosed
US-7495001-B2 Benzannelated derivatives, their manufacture and use as pharmaceutical agents HOFFMANN-LA ROCHE INC. (US) 2009-02-24 — — US disclosed
CN-1875001-A Benzocyclolated compounds as PPAR activators HOFFMANN LA ROCHE (CH) 2006-12-06 — — CN disclosed
EP-1682507-A1 BENZANNELATED COMPOUNDS AS PPAR ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2006-07-26 — — EP disclosed
WO-2005049572-A1 BENZANNELATED COMPOUNDS AS PPAR ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2005-06-02 — — WO disclosed
US-20050096336-A1 Benzannelated derivatives, their manufacture and use as pharmaceutical agents HOFFMANN-LA ROCHE INC. 2005-05-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190071435-A1 GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES GPR119, GLP1R, GCGR CYP4F2 2590/4885CYP4A11 631/4885CYP1A2 2174/4885
US-20100190831-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF GPR119, GPR52, GCGR CYP4F2 1483/4885CYP4A11 1325/4885CYP1A2 1721/4885
US-10118922-B2 GPR120 agonists for the treatment of type II diabetes GPR119, GLP1R, GCGR CYP4F2 2590/4885CYP4A11 631/4885CYP1A2 2174/4885
US-20050096336-A1 Benzannelated derivatives, their manufacture and use as pharmaceutical agents PPARD, PPARA, PPARG CYP4F2 442/4885CYP4A11 100/4885CYP1A2 153/4885
US-10618893-B2 GPR120 agonists for the treatment of type II diabetes GPR119, GLP1R, GCGR CYP4F2 2590/4885CYP4A11 631/4885CYP1A2 2174/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.